Riluzole

Cat. No.: HY-B0211
CAS No.: 1744-22-5
Molecular Formula: C₈H₅F₃N₂OS
Molecular Weight: 234.2
Target: Sodium Channel; GABA Receptor
Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:
- Powder
  -20°C  3 years
  4°C   2 years
- In solvent
  -80°C  6 months
  -20°C  1 month

SOLVENT & SOLUBILITY

In Vitro
DMSO : 100 mg/mL (426.99 mM; Need ultrasonic)
H₂O : 1 mg/mL (4.27 mM; ultrasonic and adjust pH to 3 with HCl)

Preparing Stock Solutions

<table>
<thead>
<tr>
<th>Solvent</th>
<th>Concentration</th>
<th>Mass (1 mg)</th>
<th>Mass (5 mg)</th>
<th>Mass (10 mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 mM</td>
<td>4.2699 mL</td>
<td>21.3493 mL</td>
<td>42.6985 mL</td>
</tr>
<tr>
<td></td>
<td>5 mM</td>
<td>0.8540 mL</td>
<td>4.2699 mL</td>
<td>8.5397 mL</td>
</tr>
<tr>
<td></td>
<td>10 mM</td>
<td>0.4270 mL</td>
<td>2.1349 mL</td>
<td>4.2699 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

In Vivo
1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (10.67 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-ß-CD in saline)
   Solubility: ≥ 2.5 mg/mL (10.67 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (10.67 mM); Clear solution

BIOLOGICAL ACTIVITY

Description
Riluzole is an anticonvulsant drug and belongs to the family of use-dependent Na⁺ channel blocker which can also inhibit GABA uptake with an IC₅₀ of 43 μM.

IC₅₀ & Target
Sodium channel[^1]
IC₅₀: 43 μM (GABA receptor)[^1]
In Vitro  
Riluzole is an anticonvulsant drug and belongs to the family of use-dependent Na\(^+\) channel blocker which can also inhibit GABA uptake with an IC\(_{50}\) of 43 \(\mu\)M. At 20 \(\mu\)M, Riluzole inhibits peak autaptic IPSCs only slightly but prolongs IPSCs reliably. It is also found that Riluzole causes a strong, concentration-dependent, readily reversible enhancement of responses to 2 \(\mu\)M GABA. At higher concentrations of Riluzole, especially 300 \(\mu\)M, GABA currents exhibit apparent desensitization during prolonged co-exposure to 2 \(\mu\)M GABA and Riluzole. The EC\(_{50}\) of Riluzole potentiation of GABA responses is about 60 \(\mu\)M\(^1\).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo  
In normal naïve rats, systemic injection of Riluzole (8 mg/kg, i.p.; n=6 rats) decreases the duration of ultrasonic but not audible vocalizations evoked by noxious stimulation of the knee joint compare to vehicle tested in the same rats (\(P<0.05\)). Systemic application of Riluzole (8 mg/kg, i.p.; n=19 rats) decreases the vocalizations of arthritic rats compare to predrug and vehicle significantly (\(P<0.05\) to 0.001). Riluzole administered into the CeA significantly decreases the duration of audible and ultrasonic vocalizations evoked by noxious stimulation of the knee compare to predrug values (n=8 rats; \(P<0.05\) to 0.01)\(^2\).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay \(^1\)  
Two-electrode voltage clamp of Xenopus oocytes expressing exogenous GABAA receptors is performed with a CA-1B high performance oocyte clamp. The extracellular recording solution is ND-96 medium. Riluzole is applied from a common tip via a gravity-driven multibarrel drug-delivery system. Data acquisition and analysis are performed with pCLAMP 6 software\(^1\).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration \(^2\)  
Adult male Sprague-Dawley rats (180 to 350 g) are housed in a temperature-controlled room and maintained on a 12-h day/night cycle with unrestricted access to food and water. Pain behaviors are measured before and 5 h after induction of a mono-arthritis in the left knee joint. To test the effects of systemic (intraperitoneal, i.p.) application of Riluzole, pain behaviors are measured 1 h postinjection of Riluzole in normal and arthritic animals. To determine effects of Riluzole into the amygdala, pain behaviors are measured 15 min after starting Riluzole application through a stereotaxically implanted microdialysis probe. To investigate site of action in the amygdala of systemically applied Riluzole, potassium channel blockers are administered into the amygdala 45 min after systemic application of Riluzole and pain behaviors are measured 15 min later, i.e., 1 h postinjection of riluzole (i.p.)\(^2\).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Pharmacol Biochem Behav. 2018 May;168:43-50.

See more customer validations on www.MedChemExpress.com

REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898  Fax: 609-228-5909  E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA